In Brief: Immunomedics
This article was originally published in The Gray Sheet
Immunomedics: Firm's CEA-Scan colorectal diagnostic imaging agent shows 60% accuracy in predicting tumor resectability in patients with known or suspected recurrent colorectal cancer, compared to 47% for computed tomography alone, according to data presented May 23 at a meeting of the American Society of Clinical Oncologists in Los Angeles. The results are part of a Phase III, 208-patient study conducted in response to FDA's May 1994 request for data to supplement the company's product license application submitted in 1991 ("The Gray Sheet" March 27, p. 39). The study results were submitted to FDA in March...
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.